Peter Libby

3.0k total citations
22 papers, 1.7k citations indexed

About

Peter Libby is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Peter Libby has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 10 papers in Cardiology and Cardiovascular Medicine and 6 papers in Molecular Biology. Recurrent topics in Peter Libby's work include Inflammatory mediators and NSAID effects (12 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). Peter Libby is often cited by papers focused on Inflammatory mediators and NSAID effects (12 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Atherosclerosis and Cardiovascular Diseases (4 papers). Peter Libby collaborates with scholars based in United States, Australia and United Kingdom. Peter Libby's co-authors include Gary B. Friedman, Stephen J. Warner, Galina K. Sukhova, Zorina S. Galis, Richard T. Lee, Kiyoshi Takayama, Michael A. Gimbrone, Guillermo García‐Cardeña, Jason Comander and Eva H.C. Tang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Annals of Internal Medicine.

In The Last Decade

Peter Libby

21 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Libby United States 14 504 441 395 346 266 22 1.7k
Luı́s Vila Spain 24 326 0.6× 464 1.1× 412 1.0× 213 0.6× 299 1.1× 62 1.7k
Chiara Cuccurullo Italy 16 288 0.6× 184 0.4× 280 0.7× 430 1.2× 255 1.0× 30 1.6k
Julia Blanco Spain 28 521 1.0× 161 0.4× 854 2.2× 537 1.6× 292 1.1× 43 2.7k
J Fabre France 22 190 0.4× 345 0.8× 664 1.7× 329 1.0× 320 1.2× 46 1.8k
Martin Kömhoff Germany 25 257 0.5× 765 1.7× 730 1.8× 158 0.5× 163 0.6× 55 2.0k
Bruno Poirier France 20 688 1.4× 274 0.6× 270 0.7× 163 0.5× 379 1.4× 27 1.5k
Christiane Viedt Germany 19 600 1.2× 98 0.2× 567 1.4× 367 1.1× 248 0.9× 22 1.9k
Quanxing Wang China 24 479 1.0× 139 0.3× 476 1.2× 114 0.3× 139 0.5× 45 1.4k
Órla P. Barry Ireland 14 337 0.7× 122 0.3× 965 2.4× 229 0.7× 131 0.5× 21 1.9k
Zouher Majd France 15 192 0.4× 158 0.4× 864 2.2× 164 0.5× 354 1.3× 24 1.5k

Countries citing papers authored by Peter Libby

Since Specialization
Citations

This map shows the geographic impact of Peter Libby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Libby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Libby more than expected).

Fields of papers citing papers by Peter Libby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Libby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Libby. The network helps show where Peter Libby may publish in the future.

Co-authorship network of co-authors of Peter Libby

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Libby. A scholar is included among the top collaborators of Peter Libby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Libby. Peter Libby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Xinyi, Miao Yu, Desheng Hu, et al.. (2025). Enhanced Trained Immunity in Peripheral Monocytes in Unstable Angina With Elevated High-Sensitivity C-Reactive Protein. JACC Basic to Translational Science. 10(7). 101300–101300.
2.
Buckley, Leo F., et al.. (2025). Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States. JACC Advances. 4(3). 101622–101622. 1 indexed citations
3.
Lincoff, A. Michael, Kausik K. Ray, William J. Sasiela, et al.. (2024). Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. Journal of the American College of Cardiology. 84(2). 152–162. 12 indexed citations
4.
Yu, Miao, Fen Yang, Jiahao Xu, et al.. (2024). Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention. JACC Asia. 4(8). 636–638. 5 indexed citations
5.
Weber, Brittany, et al.. (2024). Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19. JAMA Network Open. 7(9). e2431309–e2431309. 4 indexed citations
6.
Yeomans, Neville D., David Y. Graham, M. Elaine Husni, et al.. (2018). Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Alimentary Pharmacology & Therapeutics. 47(11). 1453–1463. 35 indexed citations
7.
Reed, Grant W., Mouin Abdallah, Mingyuan Shao, et al.. (2018). Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. Journal of the American College of Cardiology. 71(16). 1741–1751. 30 indexed citations
8.
9.
Solomon, Daniel H., M. Elaine Husni, Katherine E. Wolski, et al.. (2017). Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis. Arthritis & Rheumatology. 70(4). 537–546. 39 indexed citations
10.
Libby, Peter, et al.. (2016). Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials. Thrombosis and Haemostasis. 116(12). 1012–1021. 47 indexed citations
11.
Minami, Manabu, Hiroshi Seno, Hideyuki Komekado, et al.. (2015). EP4 Receptor–Associated Protein in Macrophages Ameliorates Colitis and Colitis-Associated Tumorigenesis. PLoS Genetics. 11(10). e1005542–e1005542. 22 indexed citations
12.
Tang, Eva H.C., Yin Cai, Chi Kin Wong, et al.. (2014). Activation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue. Journal of Lipid Research. 56(2). 358–368. 25 indexed citations
13.
Tang, Eva H.C., Peter Libby, Paul M. Vanhoutte, & Aimin Xu. (2011). Anti-inflammation Therapy by Activation of Prostaglandin EP4 Receptor in Cardiovascular and Other Inflammatory Diseases. Journal of Cardiovascular Pharmacology. 59(2). 116–123. 69 indexed citations
14.
15.
Takayama, Kiyoshi, Guillermo García‐Cardeña, Galina K. Sukhova, et al.. (2002). Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor. Journal of Biological Chemistry. 277(46). 44147–44154. 292 indexed citations
16.
Kranzhöfer, Roger, et al.. (1999). Systemic Thrombin Inhibition by Hirulog Does Not Alter Medial Smooth Muscle Cell Proliferation and Inflammatory Activation after Vascular Injury in the Rabbit. Cardiovascular Drugs and Therapy. 13(5). 429–434. 11 indexed citations
17.
Libby, Peter. (1998). Diabetes and vascular diseases.. PubMed. 52(5). 403–5. 2 indexed citations
18.
Libby, Peter, Galina K. Sukhova, Richard T. Lee, & Zorina S. Galis. (1995). Cytokines Regulate Vascular Functions Related to Stability of the Atherosclerotic Plaque. Journal of Cardiovascular Pharmacology. 25. S9–S12. 318 indexed citations
19.
Libby, Peter, Stephen J. Warner, & Gary B. Friedman. (1988). Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids.. Journal of Clinical Investigation. 81(2). 487–498. 450 indexed citations
20.
Maroko, Peter R., Dennis M. Davidson, Peter Libby, Arthur D. Hagan, & Eugene Braunwald. (1975). Effects of Hyaluronidase Administration on Myocardial Ischemic Injury in Acute Infarction. Annals of Internal Medicine. 82(4). 516–520. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luı́s Vila Breakdown of academic impact, for papers by Chiara Cuccurullo Breakdown of academic impact, for papers by Julia Blanco Breakdown of academic impact, for papers by J Fabre Breakdown of academic impact, for papers by Martin Kömhoff Breakdown of academic impact, for papers by Bruno Poirier Breakdown of academic impact, for papers by Christiane Viedt Breakdown of academic impact, for papers by Quanxing Wang Breakdown of academic impact, for papers by Órla P. Barry Breakdown of academic impact, for papers by Zouher Majd
Rankless by CCL
2026